Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT-01 in Relapsed or Refractory T-cell Lymphoma
NCT05387226Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of RT-01 in T-cell lymphoma, sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: Incidence of adverse events up to 6 months, Objective Response Rate up to 2 years and 6 more. Status: unknown.
02
Drugs
RT-01
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05387226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387226.